A hydrogen-bonded organic framework (HOF) and a method of making the HOF. The HOF has at least one amine substituted organic linker and at least one carboxylic acid-based organic linker. The HOF is prepared by dissolving the linkers separately in water and mixing the aqueous solutions, without using any organic solvents, additional catalysts, or any other reagents.

Substituted aromatic sulfonamides of formula (I)

##STR00001##

pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

Substituted aromatic sulfonamides of formula (I)

##STR00001##

pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

A compound represented by a formula (I) or a salt thereof; and a herbicide containing at least one selected from the group consisting of the compound and a salt thereof as an active ingredient.

##STR00001##

wherein R.sup.a and R.sup.b each independently represent a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl group, or the like; X.sup.1 and X.sup.2 each independently represent a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl group, or the like; X.sup.3 represents a hydrogen atom, a substituted or unsubstituted C.sub.1-6 alkyl group, or a halogeno group; X.sup.4 represents a hydrogen atom or a halogeno group; R.sup.2 represents a substituted or unsubstituted C.sub.1-6 alkyl group, or the like; Q represents a group represented by a formula (Q1), or the like; and in the formula (Q1), an asterisk (*) indicates a bonding position with an R.sup.a-substituted nitrogen atom, and each R.sup.1 independently represents a hydrogen atom or a substituted or unsubstituted C.sub.1-6 alkyl group.

N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of formula I and their use as herbicides,

##STR00001##

The invention relates to N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of formula I and their use as herbicides. In said formula I, B represents N or CH, whereas R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 represent groups such as hydrogen, halogen or organic groups such as alkyl or phenyl.

N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of formula I and their use as herbicides,

##STR00001##

The invention relates to N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamides of formula I and their use as herbicides. In said formula I, B represents N or CH, whereas R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 represent groups such as hydrogen, halogen or organic groups such as alkyl or phenyl.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, hematological disorders, neurological disorders and respiratory diseases are disclosed herein.